Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.

The global community-acquired bacterial pneumonia (CABP) treatment drugs market is estimated to be valued at US$ 1,269.73 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).

Figure 1. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Value (US$ Mn), by Region, 2020

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs  | Coherent Market Insights

The increasing prevalence of community-acquired pneumonia is expected to propel growth of the global community-acquired bacterial pneumonia (CABP) treatment drugs market

High prevalence of community-acquired pneumonia is expected to propel demand for community-acquired bacterial pneumonia (CABP) treatment drugs, which is expected to drive the market growth over the forecast period. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that the incidence of all?cause CAP each year was estimated at 0.81 per 1,000 individuals , rising to 6.95 per 1,000 person year in those aged 75 or older in Central Vietnam.

Moreover, increasing incidence of CAP were dominated by the effect of HIV. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that in 2017, the incidence of CAP were dominated by HIV if untreated, which was associated with a 17? to 35?fold increase in pneumococcal pneumonia in Sub-Saharan Africa region.

However, inappropriate treatment due to incorrect identification of pathogen contribute to the limited use of current drugs in the management of CABP. For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), the presence of multiple pathogens in patients leads to incorrect selection of initial antibiotic, which may affect the mortality outcome in CABP. Such inappropriate medication are expected to hamper the market growth.

Figure 2. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Share (%), by Drug Class, 2020

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs  | Coherent Market Insights

Increasing incidence of CAP in North America is expected to boost the market growth

North America is expected to hold dominant position in the global community-acquired bacterial pneumonia (CABP) treatment drugs market, owing to rising incidence of community-acquired pneumonia in the region especially in the U.S. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that in the U.S. overall incidence of community-acquired pneumonia in adults was around 2.5 per 1000 person, rising to 6.3 and 16.4 per 1000 person in adults aged 65-79 and 80 years or older in 2017. Furthermore, according to the Centers for Disease Control and Prevention (CDC), an article published in 2018 states that, around 6 million cases  of community-acquired pneumonia were reported annually, resulting in an estimated 4.2 million ambulatory care visits, with adults age 65 and older most vulnerable to CAP.

request-sample

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 1,269.73 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 7.2% 2027 Value Projection: US$ 2,075.34 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, Others.
  • By Dose Form: Solution, Tablet.
  • By Route of Administration: Oral, Intravenous.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.

Growth Drivers:
  • Increasing prevalence of community-acquired bacterial pneumonia
  • Product launches amongst key players
  • Robust product pipeline
Restraints & Challenges:
  • Inadequate penetration of antibacterial agents
  • Antibiotic resistance in drugs

Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global community-acquired bacterial pneumonia (CABP) treatment drugs market during the forecast period.

Key Players

Major players operating in the global community-acquired bacterial pneumonia (CABP) treatment drugs market include Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.

Community-acquired bacterial pneumonia (CABP) is most common acute respiratory illnesses among various infections triggering sepsis. Microbiologically, bacteria are common agents causing pneumonia, with Streptococcus pneumoniae being the most common cause worldwide. CABP is the most common infectious causes of illness and hospitalization, especially in the geriatric population. For instance, according to the National Center for Biotechnology Information (NCBI), in March 2020, the incidence of community-acquired pneumonia (CAP) in the U.S. is more than 5 million per year.

Market Dynamics

Inorganic strategies amongst key players are strengthening the companies’ market share in global community-acquired bacterial pneumonia (CABP) treatment drugs market. For instance, in 2017, Avir Pharma Inc. (Avir), an affiliate of the Laboratoire RIVA Group, entered into a Canadian distribution and license agreement with Basilea Pharmaceutica Ltd. for its antifungal Cresemba (isavuconazole) and antibiotic Zevtera (ceftobiprole). Avir plans to apply for a marketing authorization for isavuconazole in Canada. Zevtera is already approved by Health Canada for the treatment of adult patients with hospital-acquired pneumonia (HAP) and for the treatment of community-acquired pneumonia (CAP) and will be purchasing product from Basilea and will commercialize in Canada.

However, antibiotic resistance in drugs is hampering the market growth. For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), in pneumococcal pneumonia, beta-lactam as monotherapy may not be optimal therapy even if bacteria remain susceptible to the beta-lactam. Therefore, antibiotic resistance are expected to restrain the global community-acquired bacterial pneumonia (CABP) treatment drugs market.

Key features of the study:

  • This report provides in-depth analysis of the global community-acquired bacterial pneumonia (CABP) treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global community-acquired bacterial pneumonia (CABP) treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global community-acquired bacterial pneumonia (CABP) treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global community-acquired bacterial pneumonia (CABP) treatment drugs market.

Detailed Segmentation:

  • Global Community-Acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class:
    • Pleuromutilin Antibiotic
    • Cephalosporin
    • Glycylcycline
    • Oxazolidinone
    • Ketolide
    • Others
  • Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form:
    • Solution
    • Tablet
  • Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration:
    • Oral
    • Intravenous
  • Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region:
    • North America
      • By Drug Class:
        • Pleuromutilin Antibiotic
        • Cephalosporin
        • Glycylcycline
        • Oxazolidinone
        • Ketolide
        • Others
      • By Dose Form:
        • Solution
        • Tablet
      • By Route of Administration
        • Oral
        • Parental
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Pleuromutilin Antibiotic
        • Cephalosporin
        • Glycylcycline
        • Oxazolidinone
        • Ketolide
        • Others
      • By Dose Form:
        • Solution
        • Tablet
      • By Route of Administration
        • Oral
        • Parental
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Pleuromutilin Antibiotic
        • Cephalosporin
        • Glycylcycline
        • Oxazolidinone
        • Ketolide
        • Others
      • By Dose Form:
        • Solution
        • Tablet
      • By Route of Administration
        • Oral
        • Parental
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Pleuromutilin Antibiotic
        • Cephalosporin
        • Glycylcycline
        • Oxazolidinone
        • Ketolide
        • Others
      • By Dose Form:
        • Solution
        • Tablet
      • By Route of Administration
        • Oral
        • Parental
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Pleuromutilin Antibiotic
        • Cephalosporin
        • Glycylcycline
        • Oxazolidinone
        • Ketolide
        • Others
      • By Dose Form:
        • Solution
        • Tablet
      • By Route of Administration
        • Oral
        • Parental
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Pleuromutilin Antibiotic
        • Cephalosporin
        • Glycylcycline
        • Oxazolidinone
        • Ketolide
        • Others
      • By Dose Form:
        • Solution
        • Tablet
      • By Route of Administration
        • Oral
        • Parental
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Nabriva Therapeutics*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Paratek Pharmaceuticals, Inc.
    • Melinta Therapeutics, Inc.
    • Allergan plc
    • Bayer AG
    • Lupin Pharmaceuticals, Inc.
    • Mylan N.V.
    • Sanofi S.A.
    • Pfizer Inc.
    • Dainippon Sumitomo Pharma
    • Takeda Pharmaceutical Company Limited
    • Basilea Pharmaceutica International AG

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Dose Form
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Community-Acquired Bacterial Pneumonia (CABP) Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Market Scenario
    • Impact of COVID-19 Market on the Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Products
  5. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Pleuromutilin Antibiotic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Cephalosporin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Glycylcycline
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Oxazolidinone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ketolide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Solution
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Tablet
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  9. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Dose Form, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Dose Form, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Dose Form, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Dose Form, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Dose Form, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Dose Form, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  1. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Nabriva Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Paratek Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Melinta Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Allergan plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
        •  
      • Lupin Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Dainippon Sumitomo Pharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Basilea Pharmaceutica International AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Analyst Views
  2. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 42 market data tables and 26 figures on "Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market” - Global forecast to 2027

FAQgrowicon

Frequently Asked Questions

The global community-acquired bacterial pneumonia (CABP) treatment drugs market size is estimated to be valued at US$ 1,269.73 million in 2020 and is expected to exhibit a CAGR of 7.2% between 2020 and 2027.
The increasing prevalence of community-acquired bacterial pneumonia, product launches amongst key players, and robust pipeline of drugs are expected to favor the market growth.
The pleuromutilin antibiotic segment is expected to be the leading drug class segment in the global community-acquired bacterial pneumonia (CABP) treatment drugs market during the forecast period (2020-2027).
North America community-acquired bacterial pneumonia (CABP) treatment drugs market is expected to generate highest revenue share during the forecast period.
Major players operating in the global community-acquired bacterial pneumonia (CABP) treatment drugs market include Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.
The value of the global community-acquired bacterial pneumonia (CABP) treatment drugs market is estimated to be US$ 1,269.73 million in 2020.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner